Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: "Walter Maksymowych" Clear advanced filters

  • MRI shows great promise as a scoring system for spinal inflammation in ankylosing spondylitis. This Viewpoint discusses the progress in the development of MRI scoring methods and the prospective use of MRI as a tool to evaluate disease activity in patients with ankylosing spondylitis.

    • Walter P Maksymowych
    • Robert GW Lambert
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 2, P: 232-233

  • Outcome assessment of disease modification represents a major challenge to the development of therapies and management of spondyloarthritis, particularly for patients with axial disease. Could a new approach to imaging assessment of the spine using low-dose CT provide an answer to this perennial problem?

    • Walter P. Maksymowych
    • Robert G. Lambert
    News & Views
    Nature Reviews Rheumatology
    Volume: 14, P: 130-131

  • Clinicians now have the therapies and outcome tools to implement treat-to-target strategies aimed at achieving and maintaining adequate function and control of symptoms in spondyloarthritis and psoriatic arthritis. However, validation of surrogate markers of structural progression is a prerequisite for treat-to-target strategies aimed at improving long-term outcomes such as joint damage.

    • Walter P. Maksymowych
    News & Views
    Nature Reviews Rheumatology
    Volume: 9, P: 507-508

  • Advances in 2012 have helped to solve several established mysteries in spondyloarthritis (SpA)—why T-cell-directed therapies have not delivered the expected efficacy and how the IL-23–IL-17 cytokine axis is linked to the specific pathology of SpA. The opportunity to influence disease progression at inflammatory lesions using anti-TNF agents may be fleeting.

    • Walter P. Maksymowych
    News & Views
    Nature Reviews Rheumatology
    Volume: 9, P: 72-74

  • Here, the authors propose that more stringent MRI definitions for inflammatory and structural lesions in the sacroiliac joints should be used in randomized controlled trials in non-radiographic axial spondyloarthritis. They argue that such an approach might enhance diagnostic accuracy and thereby increase discrimination between therapies.

    • Walter P. Maksymowych
    • Robert G. W. Lambert
    • Mikkel Østergaard
    Reviews
    Nature Reviews Rheumatology
    Volume: 18, P: 481-489

  • Any form of treatment for patients with ankylosing spondylitis (AS) is defined as being disease-modifying on the basis of its ability to decrease inflammation, improve function and inhibit the progression of structural damage. This Review outlines clinical outcomes that are relevant to the concept of disease modification, looks at what is known about the disease-modifying properties of currently available agents and considers the challenges involved in developing future therapies for AS.

    • Walter P. Maksymowych
    Reviews
    Nature Reviews Rheumatology
    Volume: 6, P: 75-81

  • Different imaging modalities, such as radiography, MRI and CT, have different advantages and can help the clinician with different aspects in assessing axial spondyloarthritis (axSpA). This Review covers imaging aspects relating to the diagnosis, classification and management of axSpA.

    • Walter P. Maksymowych
    Reviews
    Nature Reviews Rheumatology
    Volume: 15, P: 657-672